drugset / Trial / NCT05021120
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours
NaSingle-groupOpen-labelTreatment
Summary
A Phase 1 study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary antitumor activity of AK127 in combination with AK104.
Timeline
- Start
- 2021-10-12
- Primary completion
- 2024-10-01
- Completion
- 2025-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LANCASTOTUG | Monoclonal antibody | — | Intravenous |
| Background | Cadonilimab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.